How to buy ProPhase Labs stock | $4.8

ProPhase Labs, Inc is a drug manufacturers-specialty & generic business based in the US. ProPhase Labs shares (PRPH) are listed on the NASDAQ and all prices are listed in US Dollars. ProPhase Labs employs 95 staff and has a trailing 12-month revenue of around 0.00.

ProPhase Labs stock price (NASDAQ: PRPH)

Use our graph to track the performance of PRPH stocks over time.

ProPhase Labs shares at a glance

• Key figures

Information last updated 2021-07-29.

Latest market close	$4.80
52-week range	$1.67 - $15.28
50-day moving average	$6.25
200-day moving average	$7.25
Wall St. target price	$22.50
PE ratio	N/A
Dividend yield	N/A (13.16%)
Earnings per share (TTM)	$-0.33

Buy ProPhase Labs shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ProPhase Labs stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ProPhase Labs, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ProPhase Labs price performance over time

Historical closes compared with the close of $4.8 from 2021-05-28

1 week (2021-07-21)	N/A
1 month (2021-07-01)	-20.13%
3 months (2021-04-30)	-9.94%
6 months (2021-01-28)	N/A

1 year (2020-07-28)	N/A
2 years (2019-07-28)	N/A
3 years (2018-07-28)	N/A
5 years (2016-07-28)	N/A

ProPhase Labs financials

Revenue TTM	$27.9 million
Gross profit TTM	$4.6 million
Return on assets TTM	-2.51%
Return on equity TTM	-1.45%
Profit margin	-0.93%
Book value	$3.48
Market capitalisation	$109.4 million

TTM: trailing 12 months

Shorting ProPhase Labs shares

There are currently 417,901 ProPhase Labs shares held short by investors – that's known as ProPhase Labs's "short interest". This figure is 9% down from 459,103 last month.

There are a few different ways that this level of interest in shorting ProPhase Labs shares can be evaluated.

ProPhase Labs's "short interest ratio" (SIR)

ProPhase Labs's "short interest ratio" (SIR) is the quantity of ProPhase Labs shares currently shorted divided by the average quantity of ProPhase Labs shares traded daily (recently around 182489.51965066). ProPhase Labs's SIR currently stands at 2.29. In other words for every 100,000 ProPhase Labs shares traded daily on the market, roughly 2290 shares are currently held short.

However ProPhase Labs's short interest can also be evaluated against the total number of ProPhase Labs shares, or, against the total number of tradable ProPhase Labs shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ProPhase Labs's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 ProPhase Labs shares in existence, roughly 10 shares are currently held short) or 0.0153% of the tradable shares (for every 100,000 tradable ProPhase Labs shares, roughly 15 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ProPhase Labs.

Find out more about how you can short ProPhase Labs stock.

ProPhase Labs share dividends

We're not expecting ProPhase Labs to pay a dividend over the next 12 months.

Have ProPhase Labs's shares ever split?

ProPhase Labs's shares were split on a 2:1 basis on 22 January 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ProPhase Labs shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ProPhase Labs shares which in turn could have impacted ProPhase Labs's share price.

ProPhase Labs share price volatility

Over the last 12 months, ProPhase Labs's shares have ranged in value from as little as $1.6676 up to $15.2846. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ProPhase Labs's is -0.1864. This would suggest that ProPhase Labs's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, ProPhase Labs has bucked the trend.

ProPhase Labs overview

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through saliva and nasal swab methods, as well as other respiratory pathogen panel testing services, including Influenza A and B, and others. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc.

Frequently asked questions

What percentage of ProPhase Labs is owned by insiders or institutions?
Currently 17.89% of ProPhase Labs shares are held by insiders and 9.563% by institutions. How many people work for ProPhase Labs?
Latest data suggests 95 work at ProPhase Labs. When does the fiscal year end for ProPhase Labs?
ProPhase Labs's fiscal year ends in December. Where is ProPhase Labs based?
ProPhase Labs's address is: 711 Stewart Avenue, Garden City, NY, United States, 11530 What is ProPhase Labs's ISIN number?
ProPhase Labs's international securities identification number is: US74345W1080 What is ProPhase Labs's CUSIP number?
ProPhase Labs's Committee on Uniform Securities Identification Procedures number is: 74345W108